EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that a Nasdaq Hearings Panel has granted the Company's request for continued listing on The Nasdaq Stock Market. The Company's continued listing is subject to the Company's satisfaction of the condition that on or before February 1, 2010, the Company evidence a closing bid price of at least $1.00 per share for a minimum of ten prior consecutive trading days (or, under certain circumstances, such longer period as the Panel may determine).

As previously announced, on August 3, 2009, EpiCept received notice from Nasdaq that it had not regained compliance with the minimum bid price requirement and that the Company's securities were subject to delisting unless it requested a hearing before a Nasdaq Hearings Panel. The Company requested a hearing and appeared before the Panel on September 23, 2009. On November 2, 2009, the Panel rendered its determination to continue the Company's listing.

The Company expects to timely comply with the terms of the Panel's decision; however, there can be no assurance that the Company will be able to do so.

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene®, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with AML in first remission. The Company has two oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors. The Company's pain portfolio includes EpiCept NP-1, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact.